Oral use of human alpha interferon in cats

Journal of Biological Response Modifiers

Volumn 7, Issue 5, 1988, Pages 513-523

  Cummins, Joseph M ^a   Tompkins, Mary B ^b   Olsen, Richard G ^c   Tompkins, Wayne A ^b   Lewis, Mark G ^c  

^a Amarillo Cell Culture   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Feline leukemia; Human alpha interferon

Indexed keywords

ALPHA INTERFERON;

ANIMAL EXPERIMENT; CAT; FELINE LEUKEMIA VIRUS; LEUKEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMAL; CATS; FEMALE; HUMAN; INTERFERON TYPE I; LEUKEMIA, EXPERIMENTAL; MALE;

EID: 0023772551     PISSN: 07326580     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Jarrett WF. Feline leukemia. Int Rev Exp Pathol 1971;10:243
2. Jarrett W, Jarrett O, Mackey L, Land H, Hardy WD Jr, Essex M. Horizontal transmission of leukemia virus and leukemia in the cat. J NatI Cancer Inst 1973;51:833-4l.
3. Sarma PD, Log T, Skuntz S, Kushnar S, Burkley K. Experimental horizontal transmission of feline leukemia viruses of subgroups A, B, and C. J NatI Cancer Inst 1978;60:871-74.
4. Cotter SM, Hardy WD Jr, Essex M. Association of feline leukemia virus with lymphosarcoma and other disorders in the cat. JAVMA 1975;166:449-54.
5. Rojko JL, Hoover EA, Mathes LE, Olsen RG, Shaller JP. Pathogenesis of experimental feline leukemia virus infection. J NatI Cancer Inst 1979;63:759-68.
6. Blakeslee JR, Rojko JL. Feline leukemia. In: Olsen RG, Krakowka S, Blakeslee JR, eds. Comparative pathobiology of viral diseases, vol 2. Boca Raton, FL: CRC Press, 1985:1-19.
7. Pederson HC, Theiler G, Keane MA et al. Studies of naturally acquired feline leukemia virus infection: changes occurring during the initial stage of infection. AJVR 1977;38:1523-31.
8. Beck ER, Harris CK, Macy DW. Feline leukemia virus: infection and treatment. Compndm Cont Ed 1986;8:567-73.
9. Hardy WD Jr, Hirshaut Y, Hess P. Detection of the feline leukemia virus and other mammalian oncornaviruses by immunofluorescence. In: Datches AM, Chieco-Bianchi L, eds. Unifying concepts of leukemia. New York: Karger, 1973:778-99.
10. Sarma PS, Log T. Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralization tests. Virology 1973;54:160-9.
11. Charman HP, Kim H, Gilden RV, Hardy WD Jr, Essex M. Humoral immune response of cats to feline leukemia virus: comparison of responses to the major structural protein P30 and to a virus-specific cell membrane antigen (FOCMA). J Natl Cancer Inst 1976;56:859-61.
12. Hoover EA, Olsen RG, Hardy WD Jr, Schalter JP, Mathes LE. Feline leukemia virus infection: age-related variation in response of cats to experimental infections. J Natl Cancer Inst 1976;57:365-9.
13. Essex M, Sliski A, Hardy WD Jr, Cotter SM. Immune response to leukemia virus and tumor-associated antigens in cats. Cancer Res 1976;36:640-5.
14. Francis DP, Essex M. Excretion of feline leukemia virus by naturally infected pet cats. Nature 1977;269:252-4.
15. Povey C. Feline leukemia. Diagnosis, treatment, and euthanasia. Vet Rec 1976;98:293-9.
16. Cotter SM. Anemia associated with feline leukemia virus infection. JAVMA 1979;175:1191-1.
17. Henness AM, Crow SE. Treatment of feline myelogenous leukemia: four case reports. JAVMA 1977;171:263-6.
18. Crow SE, Madewell BR, Henness AM. Feline reticuloendotheliosis: a report of four cases. JAVMA 1977;170:1329-32.
19. Henness AM, Crow SE, Anderson BC. Monocytic leukemia in three cats. JAVMA 1977;170:1325-8.
20. Stann SE. Myelomonocytic leukemia in a cat. JAVMA 1979;174:722-5.
21. Cotter SM, Gilmore CE, Rollins C. Multiple cases of feline leukemia and feline infectious peritonitis in a household. JAVMA 1973;162:1054-8.
22. Loar AS. The management of feline lymphosarcoma. Vet Clin North Am: SA Pract 1984;14:1299- 1330.
23. Cockerell GL, Hoover EA, Krakowka S. Lymphocyte mitogen reactivity and enumeration of circulating B- and T-cells during feline leukemia virus infection in the cat. J NatI Cancer Inst 1976;57:1095-9.
24. Cockerell GL, Hoover EA. Inhibition of normal lymphocyte mitogenic reactivity by serum from feline leukemia virus-infected cats. Cancer Res 1976;37:3985-9.
25. Orosz CG, Zinn NE, Olsen RG, Mathes LE. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines. J Immunol 1985;134:3396-3403.
26. Orosz CG, Zinn NE, Olsen RG, Mathes LE. Retrovirus-mediated immunosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behavior by reversibly impairing lymphocyte secretion. J Immunol 1985;135:583-90.
27. Engleman RW, Fulton RW, Good RA, Day NK. Suppression of gamma interferon production by inactivated feline leukemia virus. Science 1985;227:1368-70.
28. Grant CK, Emisse BJ, Pontefract R. Comparison of feline leukemia virus-infected and normal cat T-cell lines in interleukin-2 conditioned medium. Cancer Res 1984;44:498-502.
29. Isaacs A, Linderman J. Virus interference. I. The interferon. Proc R Soc Lond [Bio] 1957; 147:258-67.
30. Havell E, Berman B, Ogburn C, Berg K, Paucker K, Vilcek J. Two antigenically distinct species of human interferon. Proc Natl Acad Sci USA 1975;72:2185-7.
31. De Ley M, Van Damme J, Claeys H, Weening H, Heine JW, Billiau A, Vermylen C, De Somer P. Production, partial purification and characterization of mitogen-induced human interferons. In: DeMaeyer E, Galasso G, Schellekens H, eds. The biology of the interferon system. Amsterdam: Elsevier, 1980:301.
32. Stewart WE II, Blalock JE, Burke DC, et al. Interferon nomenclature. Nature 1980;286:110.
33. Kirchner H, Marcucci F. Interferon production by leukocytes. In: Vilcek J, DeMaeyer E, eds. Interferons, vol 2: interferons and the immune system. Amsterdam: Elsevier, 1984:7-34.
34. Vogel SN, Friedman RM. Interferon and macrophages: activation and cell surface changes. In: Vilcek J, DeMaeyer E, eds. Interferons, vol 2: interferons and the immune system. Amsterdam: Elsevier, 1984:35-9.
35. Herberman RB. Interferon and cytotoxic effector cells. In: Vilcek J, DeMaeyer E, eds. Interferons, vol 2: interferon and the immune system. Amsterdam: Elsevier, 1984:61-84.
36. Bonavida B, Wright SC. Natural killer cytotoxic factors (NKCF) role in cell-mediated cytotox-icity. In: Lotzova E, Herberman RB, eds. Immunobiology of natural killer cells, vol 1. Boca Raton, FL: CRC Press, 1986:125.
37. Sonnenfeld G. Effects of interferon on antibody formation. In: Vilcek J, DeMaeyer E, eds. Interferons, vol 2: interferon and the immune system. Amsterdam: Elsevier, 1984:85-99.
38. Farrar JJ, Benjamin WR, Steeg PS. Regulatory interactions between the interferons and the interleukins. In: Vilcek J, DeMaeyer E, eds. Interferons, vol 2: interferons and the immune system. Amsterdam: Elsevier, 1984:101-12.
39. Cavalieri RL, Havell EA, Vilcek J, Pestka S. Synthesis of human interferon by Xenopus laevis oocytes: two structural genes for interferons in human cells. Proc Natl Acad Sci USA 1977; 74:3287-91.
40. Schgal PB. How many human interferons are there? In: Gresser I, ed. Interferon, vol 4. London: Academic Press, 1982:22.
41. Stewart II WE. Chapter VII. Interferons: their purification and characterization. In: Stewart II WE, ed. The interferon system. New York: Springer Verlag, 1982:134-83.
42. Tompkins MB, Cummins JM. Response of FeLV-induced nonregenerative anemia to oral administration of a bovine interferon-containing preparation. Feline Practice 1982;12:6-15.
43. Schafer TW, Lieverman M, Cohen M, Came PE. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science 1972;176:1326-7.
44. Van Hoffman W. Danner K, Seeger K. Erste Erfahrungen bei der Behandlung von virusbedingten kalberdurchfallen mit gentechnisch erzeugtem interferon. Disch Tieraztl WSchr 1985;92:278-80.
45. Cummins JM, Rosenquist BD. Protection of calves against rhinovirus infection by nasal secretion interferon induced by infectious bovine rhinotracheitis virus. AJVR 1980;41:161-5.
46. Rohovsky MW, Greisemer RA, Wolfe LG. The germ-free cat. Lab Anim Care 1966,16:52-9.
47. Rickard CG, Post JE, Noronha F, et al. A transmissible virus-induced lymphocytic leukemia of the cat. J Natl Cancer Inst 1969;43:987-1014.
48. Cantell K, Hirvonen S, Kauppinen HL, Myllyla G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981;78:27-38.
49. Cantell K, Hirvonen S, Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol 1981; 78:499-505.
50. Rosenquist BD, Loan RW. Interferon production with strain SF-4 of parainfluenza-3 virus. AJVR 1967;28:619-28.
51. Hoover EA, Mathes LE, Rojko JL, Schaller JP, Olsen RG. Modifications of the immunofluores-cence assay for feline leukemia virus group-specific antigens. AJVR 1978;39:1877-80.
52. Essex M, Snyder SP. Feline oncornavirus-associated cell membrane antigen. I. Serologie studies with kittens exposed to cell-free materials from various feline fibrosarcomas. J Natl Cancer Inst 1973;51:1007-12.
53. Essex M, Klein G, Snyder SP, et al. Feline sarcoma virus (FSV)-induced tumors: correlation between humoral antibody and tumor regression. Nature 1971; 233:195-7.
54. Scott GM, Wallace J, Tyrrell DAJ, Cantell K, Secher DS, Stewart WE. Interim report on studies on “toxic” effects of human leukocyte-derived interferon alpha (HuIFNa). J Int Res 1982;2:127- 31.
55. Ahl R, Straub OC. Comparison of interferon production in cattle after intranasal infection with parainfluenza -3 live vaccine and avirulent IBR/IPV-herpesvirus. Zentralbl Veterinarmed [B] 1985;32:407-16.
56. Cantell K, Pyhala L. Circulating interferonin rabbits after administration of human interferon by different routes. J Gen Virol 1973;20:97-104.
57. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following IV infusion and bolus, Im, and PO administrations to African green monkeys. J IFN Res 1984; 4(3):399-409.
58. Gibson DM, Cotler S, Spiegel HE, Colburn WA. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J IFN Res 1985;5:403-8.
59. Quesada JR, Gutterman JU, Hersh EM. Treatment of hairy cell leukemia with alpha interferons. Cancer 1986;57:1678-80.
60. Castaigne S, Sigaux F, Cantell K, et al. Interferon alpha in the treatment of hairy cell leukemia cancer. Cancer 1986;57:1681-4.
61. Douglas RM, Moore BW, Miles HB, et al. Prophylactic efficacy of intranasal alpha2-interferon against rhinovirus infections in the family setting. N Engl J Med 1986;314:65-70.
62. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM, Jr. Prevention of natural colds by contact prophylaxis with intranasal alpharinterferon. N Engl J Med 1986;314:71-5.
63. Lawrence JE, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986;315:1059-64.
64. Vance JC, Bart FJ, Hansen RC, et al. Intralesional recombinant alpharinterferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7.
65. Leventhal BG. Treatment of virus-associated tumors and papillomas with interferons. In: Finter NB, Oldham RK, eds. Interferon, vol 4: in vivo and clinical studies. Amsterdam: Elsevier, 1985:325-35.
66. Gall SA, Hughes CE, Trofalter K. Interferon for the therapy of condyloma acuminata. Am J Obstet Gynecol 1985; 153:157-63.
67. Androphy EJ, Dvoretzky I, Malvish AE, Wallace HJ, Lowy DR. Response of warts in epider-modysplasia verruciformis to treatment with systemic and intralesional alpha interferon. J Am Acad Dermatol 1984;11:197-202.
68. Canellos GP. Interferon in the treatment of malignant lymphoma. Semin Oncol 1985;12:25-9.
69. Legha SS. Interferons in the treatment of malignant lymphoma. Cancer 1986;57:1675-7.
70. Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-9.
71. Finter NB, Oldham RK, eds. Part III: Studies in patients with cancer. In: Interferon, vol 4: in vivo and clinical studies. Amsterdam: Elsevier, 1985:235-49.
72. Bottomley JM, Toy JL. Clinical side effects and toxicities of interferon. In: Finter NB, Oldham RK, eds. Interferon, vol 4; in vivo and clinical studies. Amsterdam: Elsevier, 1985:155-80.
73. Ahl R, Rump A. Assay of bovine interferons in cultures of the porcine cell line IB-RS-2. Infect Immunol 1976;14:603-6.
74. Babiuk LA, Rouse BT. Bovine type II interferon: activity in heterologous cells. Intervirology 1977;8:250-6.
75. Gresser I, Bandu MT, Brouty-Boye D, Tovey M. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature 1974;251:543-5.
76. Jameson P, Dixon MA, Grossberg SE. A sensitive interferon assay for many species of cells: EMC virus hemagglutinin yield-reduction. Proc Soc Exp Biol Med 1977;155:173-8.
77. Lin LS, Wiranowska-Stewart M, Chudzio T, Stewart WE II. Characterization of the heterogenous molecules of human interferons: differences in the cross-species antiviral activities of various molecular populations in human leukocyte interferons. J Gen Virol 1978;39:125-30.
78. Paucker K, Dalton BJ, Torma ET, Ogburn CA. Biological properties of human leukocyte interferon components. J Gen Virol 1977;35:341-51.
79. Pollikoff R, Donikian MA, Padron A, Liu OC. Tissue specificity of interferon prepared in various tissue cultures. Proc Soc Exp Biol Med 1962;110:232-4.
80. Tovey MG, Bandu MT, Begon-Lours J, Brouty-Boye D, Gresser I. Antiviral activity of bovine interferons on primate cells. J Gen Virol 1977;36:341-4.
81. Capon DJ, Shepart HM, Goeddel DV. Two distinct families of human and bovine interferon-a genes are coordinately expressed and encode functional polypeptides. Mol Cell Biol, 1985;5:768- 79.
82. Leung DW, Capon DJ, Goeddel DV. The structure and bacterial expression of three distinct bovine interferon-ß genes. Biotechnology 1984:458-64.
83. Desmyter J, Stewart WE. Molecular modification of interferon: attainment of human interferon in a conformation active on cat cells but inactive on human cells. Virology 1976;70:451-S.
84. Jameson P, Essex M. Inhibition of feline virus replication by human leukocyte interferon. Antiviral Res 1983;3:115-20.
85. Fulton RW, Burge LJ. Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons. Antimicrob Agents Chemother 1985;28:698-9.
86. Sen GC, Herz R, Davatelis V, Pestka S. Antiviral and protein-inducing activities of recombinant human leukocyte interferons and their hybrids. J Virology 1984;50:445-50.
87. Cocker FM, Howard PE, Harbour DA. Effect of human a-hybrid interferon in the course of feline viral rhinotraceitis. Vet Record 1987;120:391-3.
88. Rudgers R, Merigan TC, Hardy WD, Old LG, Kassel R. Cat interferon inhibits feline leukemia virus infection in cell culture. Nature New Biol 1972;237:270-l.
89. Yamamoto JK, Ho E, Pedersen NC. A feline retrovirus-induced T-lymphoblastoid cell-line that produces an atypical alpha type of interferon. Vet Immunol Immunopathol 1986;11:1-19.
90. Engelman RW, Fulton RW, Good RA, Day NK. Suppression of gamma interferon by inactivated feline leukemia virus. Science 1985;227:1368-70.
91. Steed VP. Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Practice 1987;17:24-30.
92. Pratt PW. Feline medicine 1st ed. Santa Barbara, CA: American Veterinary Publications, 1983:123-33.
93. Yamamoto JK, Good RA, Johnson HM, et al. Augmentation of serum interferon titer prior to remission in cats treated with ex vivo immunoadsorption. Fed Proc 1983;42:838.
94. Day NK, Engelman RW, Liu WT, Trang L, Good RA. Remission of lymphoma leukemia in cats following ex vivo immunosorption therapy using staphylococcus protein A. J Biol Response Mod 1984;3:278-S5.
95. Engelman RW, Good RA, Day NK. Clearance of retroviremia and regresssion of malignancy in cats with leukemia-lymphoma during treatment with staphylococcal protein A. Cancer Detect Prevent 1987;10:435-44.
96. Abrams D, Gottlieb M, Grieco M, Speer M, Bernstein S, eds. AmFAR directory of experimental treatments for AIDS & ARC, vol 1, New York: Mary Ann Liebert, 1987:1-57.
97. Diez RA, Perdereau B, Falcoff E. From old results to new perspectives: a look at interferon’s fate in the body. J IFN Res 1987;7:553-7.
98. Liu WT, Good RA, Leim QT, et al. Remission of leukemia and loss of feline leukemia virus in cats injected with staphylococcus protein A: association with increased circulating interferon and complement-depending cytotoxic antibody. Proc Natl Acad Sci USA 1984;81:6471-5.
99. Hoover EA, Mullins JI, Quackenbush SL, Gasper PW. Pathogenesis of feline retrovirus-induced cytopathic diseases: acquired immune deficiency syndrome and aplasticanemia. In: Salzman L, ed. Animal models of retrovirus infection and their relationship to AIDS. New York: Academic Press, 1986:59-74.